|
News
2008 – 2007 – 2006 – 2005
December 19, 2006
Amorfix Receives Support from Canadian Government to Accelerate Development of Blood Test for Alzheimer's Disease
Amorfix Life Sciences Ltd., a company focused on diagnostics and treatments for brain wasting diseases, announced today that in addition to their own investment, the National Research Council Canada Industrial Research Program (NRC-IRAP) will share in the research and development of the company's proposed diagnostic test for Alzheimer's disease, via a contribution of $322,000. More
December 6, 2006
Amorfix CEO, George Adams, Accepts Congratulations at TSX Listing Ceremony, TSX Broadcast Centre
December 4, 2006
Canadian Company’s Medical Technology Lauded by World Economic Forum as Having “Dramitc and Ssustainable Impact on Society”
Amorfix Life Sciences Ltd. of Toronto will be the only Canadian recipient of 47 organizations from around the world to be named as a “Technology Pioneer” by the World Economic Forum at its prestigious annual meeting in Davos, Switzerland in January 2007. More
For our CEO's response to this honour, please click here.
November 28, 2006
Amorfix Appoints Dr. Hans Black as a New Director
Amorfix Life Sciences is pleased to announce the appointment of Dr. Hans Black to the company’s Board of Directors. More
October 2, 2006
Amorfix Extends Epitope Protection Technology to Detect Sheep Scrapie Prions in Blood
Amorfix Life Sciences Ltd. announced today that it has adapted its Epitope Protection (EP) technology platform for detection of sheep scrapie prions in blood. More
September 18, 2006
Amorfix CEO Interviewed on CBC Radio One
Dr. George Adams, President and CEO of Amorfix Life Sciences Ltd. was interviewed on CBC Radio One. To hear the broadcast click here.
September 12, 2006
Ontario Genomics Institute Completes Second Investment in Amorfix to Accelerate Development of a Blood Test for Alzheimer’s Disease
Amorfix Life Sciences Inc. announced the issue of 47,619 common shares and 23,810 warrants to Genomics Ontario Inc., the investment arm of the Ontario Genomics Institute (OGI), for gross proceeds of $50,000. This is the second investment by OGI in support of Amorfix’s development of a blood diagnostic test for Alzheimer’s disease. More
September 5, 2006
Amorfix Achieves Technical Milestone in Development of a Blood Test for Alzheimer’s Disease
Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced today the achievement of the technical milestone of demonstrating that Amorfix’s Epitope Protection (EP) technology is able to detect protected sites within Abeta amyloid aggregates which are formed in Alzheimer’s disease. More
August 3, 2006
Amorfix and Biogen Idec to Collaborate on Research for ALS Disease
Amorfix Life Sciences Ltd. (TSXV: AMF), an emerging Canadian theranostics company, announced today that it has entered into a research and investment agreement with Biogen Idec (NASDAQ: BIIB) of Cambridge, Massachusetts. More
June 21, 2006
Amorfix Announces Leading Sensitivity for Prion Detection in Spiked Human Blood Samples
Amorfix Life Sciences Ltd. announced today it had completed the analysis of the international reference blinded panels of human blood samples spiked with prions from variant Creutzfeldt-Jakob Disease (vCJD) patients which were provided by the UK government. More
June 16, 2006
Amorfix Announces William Lambert Joins Board
Amorfix Life Sciences Ltd. announced today the appointment of William Lambert to the Board of Directors and the resignation of Dr. Donald Rix as Director. More
June 12, 2006
Amorfix Reports Annual Results for Fiscal 2006
More
May 25, 2006
Amorfix Issues Stock Options
Amorfix Life Sciences Ltd. reports that it has granted 100,000 options to an investor relations consultant. More
April 4, 2006
Amorfix In-Licenses Second Novel Technology to Strenghten its ALS Therapeutic Program
Amorfix Life Sciences Ltd. reported today that it has obtained the exclusive worldwide rights to additional novel targets on Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS). More
March 24, 2006
Amorfix Completes Private Placement Financing
Amorfix Life Sciences Ltd. announced today that it has closed its previously announced private placement offering through Blackmont Capital Inc. of 4,058,823 common shares at a price of $0.85 per share for gross proceeds of $3,450,000, including the issue of 529,412 common shares pursuant to the exercise of entire amount of the over-allotment option. More
March 3, 2006
Amorfix Announces Private Placement Financing
Amorfix Life Sciences Ltd. announced today that it has entered into an agreement with Blackmont Capital Inc. as its Agent for an equity private placement, to proceed on a best efforts basis at a price of $0.85 per share for a minimum of $2,000,000 and a maximum of $3,000,000. More
February 2, 2006
Amorfix In-Licenses Novel Technology To Begin Therapeutic Program For Neurodegenerative Diseases
Amorfix Life Sciences Ltd. reported today that it has obtained an exclusive worldwide license to novel targets on Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS). The company also obtained an exclusive five-year option to acquire the intellectual property and know how surrounding the licensed technology. More
January 31, 2006
Amorfix and The Ontario Genomics Institute Announce Partnership To Accelerate Development Of A Blood Test for Alzheimer's Disease
Amorfix Life Sciences Ltd. and the Ontario Genomics Institute (OGI) announced today they are entering into a partnership to develop a blood test for Alzheimer’s disease, EP-AD™, based upon Amorfix’s patent-pending Epitope Protection technology. More
January 26, 2006
Amorfix Reports Identification Of Epitopes On Bovine Prion Protein And Approval Of Laboratory For BSE Samples
Amorfix Life Sciences Ltd. today reported that it has completed the first step towards adapting its patent pending Epitope Protection technology to detecting bovine prions, the infectious aggregated misfolded proteins that cause BSE (or Mad Cow Disease). More
|
